UCB Ventures
Overview
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 by UCB, a global biopharmaceutical company focused on neurology and immunology disorders. The fund invests in early-stage companies in the US and Europe, focusing on novel therapeutic modalities, platforms and assets that address novel biology .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Switch Therapeutics | Mar 2023 | Series A | Lead |
| Rinri Therapeutics | Jan 2025 | Series A | Co-investor |
| Iris Medicine | May 2020 | Seed | Co-investor |
| StrideBio | Mar 2021 | Series B | - |
| SpliceBio | Jun 2025 | Series B | - |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is UCB Ventures based?
Headquarters information for UCB Ventures is not publicly available.
When was UCB Ventures founded?
UCB Ventures was founded in 2017.
How many portfolio companies does UCB Ventures have?
UCB Ventures has 12 portfolio companies in Caplight's dataset.
What are some companies in UCB Ventures's portfolio?
Portfolio companies visible on Caplight include Switch Therapeutics, Rinri Therapeutics, Iris Medicine, StrideBio, SpliceBio.
What was UCB Ventures's most recent investment shown here?
UCB Ventures's most recent investment in this portfolio sample was in SpliceBio in 2025.
What sectors does UCB Ventures focus on?
UCB Ventures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does UCB Ventures focus on?
UCB Ventures typically invests at the Early stage.
What is UCB Ventures's AUM?
UCB Ventures's assets under management are estimated between $100.0M and $250.0M.